Form D · Biotechnology
Biommune Technologies Inc.
Vancouver, A1 · CIK 0001659574
Offering snapshot reported Nov 30, 2015 · SEC filing
- Reported sold
- $600K Offering amount: $600K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 18, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 30, 2015 | Initial | $600,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-252110
Amounts represent Canadian Dollar
Units consisting of one common share and one share purchase warrant
Source: Form D, filed Nov 30, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jens Biertumpel | Director |
| Judi Dalling | Executive |
| Reinhard Gabathuler | Executive |
| Patrick W. Gray | Executive |
| Michael Hutchison | Director |
| Rob Hutchison | Director |
| Karoly Nikolich | Director |
| Terry Pearson | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Suite 1780 400 Burrard St.
Vancouver, A1, V6C 3A6
Vancouver, A1, V6C 3A6